Quantifying the Ki-67 Heterogeneity Profile in Prostate Cancer

Figure 1

Ki-67% at (a) increasing PSA ranges, (b) clinical T stages, (c) increasing Gleason scores, and (d) NCCN risk groups.

(a)

(b)

(c)

(d)